Susquehanna Venture Capital

Susquehanna Venture Capital is the venture and private equity arm of Susquehanna International Group (SIG), a global quantitative trading firm headquartered in Bala Cynwyd, Pennsylvania, deploying $25M+ cheques at Series C, Series D+, and growth into mature operational technology platforms, including Health IT software. The firm benefits from SIG’s deep balance sheet, long-term capital base, and quantitative discipline that informs its investing approach. For founders, Susquehanna is best positioned as a late-stage growth lead for capital-efficient operational technology businesses (including dense health IT) approaching Series C or D scale, with audited revenue, durable economics, and clear paths to public market or strategic exit. The right founder profile is a Series C-or-later operator (typically US-headquartered or strongly US-anchored) building enterprise health IT software with $30M+ revenue, durable retention, and credible exit pathways. Founders running early-stage digital health, AI software without commercial depth, asset-heavy clinic chains, or pure consumer wellness brands are a poor fit. The cleanest entry path is via a sell-side banker with US growth equity practice depth, a Susquehanna portfolio CEO, or warm introductions from US growth funds that co-invest. In the pitch, lead with audited financials, segment-level unit economics, governance maturity, regulatory posture (HIPAA, HITECH), and a credible exit pathway. Caveats: AI focus is not stated and Susquehanna is generalist late-stage growth; AI-heavy diligence relies on external advisers. Term sheets carry institutional governance provisions, partners expect active board engagement, and cycle times are months given the firm’s underwriting depth. Susquehanna prefers concentrated positions and proprietary deal flow, so founders should engage early off-market when possible. Indian or other emerging-market exposure is selective and opportunistic rather than thesis-driven.